Protective effect of lodoxamide tromethamine on allergen inhalation challenge

G. D. Watt, T. C. Bui, Againdra K. Bewtra, R. G. Townley

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.

Original languageEnglish
Pages (from-to)286-294
Number of pages9
JournalJournal of Allergy and Clinical Immunology
Volume66
Issue number4
StatePublished - 1980

Fingerprint

Allergens
Inhalation
Mast Cells
Inhalation Administration
Cromolyn Sodium
Bronchoconstriction
Anaphylaxis
Macaca mulatta
Placebos
lodoxamide tromethamine
lodoxamide ethyl
Water
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology
  • Immunology and Allergy

Cite this

Protective effect of lodoxamide tromethamine on allergen inhalation challenge. / Watt, G. D.; Bui, T. C.; Bewtra, Againdra K.; Townley, R. G.

In: Journal of Allergy and Clinical Immunology, Vol. 66, No. 4, 1980, p. 286-294.

Research output: Contribution to journalArticle

@article{d5ac576e437d4851a0752b073e7285ed,
title = "Protective effect of lodoxamide tromethamine on allergen inhalation challenge",
abstract = "Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.",
author = "Watt, {G. D.} and Bui, {T. C.} and Bewtra, {Againdra K.} and Townley, {R. G.}",
year = "1980",
language = "English",
volume = "66",
pages = "286--294",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Protective effect of lodoxamide tromethamine on allergen inhalation challenge

AU - Watt, G. D.

AU - Bui, T. C.

AU - Bewtra, Againdra K.

AU - Townley, R. G.

PY - 1980

Y1 - 1980

N2 - Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.

AB - Lodoxamide tromethamine (U-42,585E) is a new drug intended for prophylaxis of mast cell-mediated allergic disease. It is a water-soluble, cromolyn-like agent with demonstrated activity in rat peritoneal mast cell assay, rat percutaneous anaphylaxis (rat PCA) and sensitized rhesus monkey airway system. Ten allergen-sensitive asthmatics were pretreated with lodoxamide (0.01, 0.1, or 1.0 mg) or placebo, then challenged with serial dilutions of allergen extract. Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction. At 0.01 mg, lodoxamide was effective in over half the subjects tested. Administration of lodoxamide by inhalation at doses of 0.1 and 1.0 mg uniformly allowed subjects to tolerate significantly larger doses of inhaled allergen. Side effects observed at these doses were minimal.

UR - http://www.scopus.com/inward/record.url?scp=0018910126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018910126&partnerID=8YFLogxK

M3 - Article

VL - 66

SP - 286

EP - 294

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -